NCT03836768View on ClinicalTrials.gov

BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 11, 2019

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

DTRMWXHS-12

DTRMWXHS-12 capsules: 150 mg, 300 mg

Trial Locations (1)

Unknown

Peking University Cancer Hospital, Beijing

All Listed Sponsors
lead

Zhejiang DTRM Biopharma

INDUSTRY

NCT03836768 - BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter